Published in Int J Parasitol on June 01, 2001
Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol (2009) 2.17
Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun (2002) 1.45
Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect Immun (2005) 1.34
Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations. Infect Immun (2004) 1.14
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect Immun (2003) 1.02
Class II-restricted protective immunity induced by malaria sporozoites. Infect Immun (2007) 1.00
Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother (2012) 0.95
Mixed allele malaria vaccines: host protection and within-host selection. Vaccine (2008) 0.94
DNA immunization with the cysteine-rich interdomain region 1 of the Plasmodium falciparum variant antigen elicits limited cross-reactive antibody responses. Infect Immun (2003) 0.92
Analysis of a Multi-component Multi-stage Malaria Vaccine Candidate--Tackling the Cocktail Challenge. PLoS One (2015) 0.86
Transcriptionally active PCR for antigen identification and vaccine development: in vitro genome-wide screening and in vivo immunogenicity. Mol Biochem Parasitol (2007) 0.81
Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America. Mem Inst Oswaldo Cruz (2011) 0.80
Malaria vaccine development and how external forces shape it: an overview. Int J Environ Res Public Health (2014) 0.79
Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities. PLoS One (2014) 0.78
Genetic vaccination approaches against malaria based on the circumsporozoite protein. Wien Klin Wochenschr (2006) 0.77
Transmission-blocking strategies: the roadmap from laboratory bench to the community. Malar J (2016) 0.77
Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet (1994) 6.01
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science (1998) 3.83
Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg (1997) 3.61
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science (1998) 3.46
Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg (1991) 3.31
Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet (1991) 3.01
Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet (1987) 2.98
The complexity of protective immunity against liver-stage malaria. J Immunol (2000) 2.92
Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci U S A (1994) 2.58
Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis (1997) 2.55
Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med (1984) 2.24
Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science (1987) 2.17
Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med (1996) 2.15
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 2.11
Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am J Trop Med Hyg (1986) 2.09
Cytotoxic T cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med (1990) 2.09
A shotgun optical map of the entire Plasmodium falciparum genome. Nat Genet (1999) 2.04
Characterization of Plasmodium falciparum sporozoite surface protein 2. Proc Natl Acad Sci U S A (1992) 2.00
Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science (1991) 1.94
Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci U S A (1998) 1.93
IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model. J Immunol (1999) 1.92
Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis (1995) 1.87
Bone marrow aspirate culture superior to streptokinase clot culture and 8 ml 1:10 blood-to-broth ratio blood culture for diagnosis of typhoid fever. Am J Trop Med Hyg (1986) 1.86
Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg (1990) 1.85
Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity (1997) 1.84
Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis (1995) 1.83
HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol (2000) 1.82
Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J Immunol (1991) 1.78
Antibodies against the Plasmodium falciparum receptor binding domain of EBA-175 block invasion pathways that do not involve sialic acids. Infect Immun (2000) 1.77
Interleukin 12 induction of interferon gamma-dependent protection against malaria. Proc Natl Acad Sci U S A (1994) 1.77
Research toward vaccines against malaria. Nat Med (1998) 1.76
IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J Immunol (1991) 1.73
Tropical medicine. BMJ (2000) 1.67
Age-dependent susceptibility to severe disease with primary exposure to Plasmodium falciparum. J Infect Dis (1998) 1.65
Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci U S A (2001) 1.63
A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei. J Immunol (1992) 1.62
Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci U S A (1991) 1.61
Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol (1995) 1.60
Exploring the transcriptome of the malaria sporozoite stage. Proc Natl Acad Sci U S A (2001) 1.59
Severe anemia in young children after high and low malaria transmission seasons in the Kassena-Nankana district of northern Ghana. Am J Trop Med Hyg (2000) 1.58
Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjugates. J Cell Biol (1992) 1.58
Incidence of symptomatic and asymptomatic Plasmodium falciparum infection following curative therapy in adult residents of northern Ghana. Am J Trop Med Hyg (2001) 1.57
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun (2001) 1.55
A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J Immunol (1998) 1.54
Immunity to malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med (1986) 1.51
Further consideration of the clonal nature of Salmonella typhi: evaluation of molecular and clinical characteristics of strains from Indonesia and Peru. J Clin Microbiol (1992) 1.50
Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis (2000) 1.48
Antigen-specific suppressor T lymphocytes in human lymphatic filariasis. N Engl J Med (1982) 1.47
Sequence of the immunodominant epitope for the surface protein on sporozoites of Plasmodium vivax. Science (1985) 1.44
Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science (1991) 1.43
Determining liver stage parasite burden by real time quantitative PCR as a method for evaluating pre-erythrocytic malaria vaccine efficacy. Mol Biochem Parasitol (2001) 1.40
A malaria sporozoite surface antigen distinct from the circumsporozoite protein. Bull World Health Organ (1990) 1.40
Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis (2001) 1.40
Duodenal string-capsule culture compared with bone-marrow, blood, and rectal-swab cultures for diagnosing typhoid and paratyphoid fever. J Infect Dis (1984) 1.38
Cellular mechanisms of nonspecific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol Lett (1990) 1.36
Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg (1993) 1.34
Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine (2000) 1.34
Characterization of the gene encoding sporozoite surface protein 2, a protective Plasmodium yoelii sporozoite antigen. Mol Biochem Parasitol (1992) 1.34
Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes. J Immunol (1996) 1.34
Nitric oxide-mediated antiplasmodial activity in human and murine hepatocytes induced by gamma interferon and the parasite itself: enhancement by exogenous tetrahydrobiopterin. Infect Immun (1994) 1.32
Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J Immunol (2000) 1.32
Use of a DNA probe to detect Salmonella typhi in the blood of patients with typhoid fever. J Clin Microbiol (1989) 1.29
Long-term persistence of sterile immunity in a volunteer immunized with X-irradiated Plasmodium falciparum sporozoites. J Infect Dis (1993) 1.28
Comparison of immunity to malaria in Sudan and Indonesia: crisis-form versus merozoite-invasion inhibition. Proc Natl Acad Sci U S A (1984) 1.28
Identification and characterization of the protective hepatocyte erythrocyte protein 17 kDa gene of Plasmodium yoelii, homolog of Plasmodium falciparum exported protein 1. J Biol Chem (1996) 1.25
Codon optimization of gene fragments encoding Plasmodium falciparum merzoite proteins enhances DNA vaccine protein expression and immunogenicity in mice. Infect Immun (2001) 1.24
Complexity of the cytokine and antibody response elicited by immunizing mice with Plasmodium yoelii circumsporozoite protein plasmid DNA. J Immunol (1995) 1.24
ELISPOT assay for detection of peptide specific interferon-gamma secreting cells in rhesus macaques. J Immunol Methods (2001) 1.24
Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol (2000) 1.24
The role of CD4+ T cells in immunity to malaria sporozoites. J Immunol (1993) 1.24
Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med (1995) 1.23
Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnology (N Y) (1995) 1.23
Chloroquine/doxycycline combination versus chloroquine alone, and doxycycline alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg (2001) 1.22
Absence of malaria mortality in villagers with chloroquine-resistant Plasmodium falciparum treated with chloroquine. Trans R Soc Trop Med Hyg (1984) 1.21
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine (1999) 1.20
Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet (1991) 1.20
Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proc Natl Acad Sci U S A (1999) 1.19
Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. J Infect Dis (1995) 1.19
Utilization of genomic sequence information to develop malaria vaccines. J Exp Biol (2003) 1.19
Reduction of suppressor T lymphocytes in the tropical splenomegaly syndrome. N Engl J Med (1984) 1.18
Optical mapping of Plasmodium falciparum chromosome 2. Genome Res (1999) 1.16
Evaluation of a DNA probe for identifying Salmonella typhi in Peruvian and Indonesian bacterial isolates. J Infect Dis (1988) 1.14
Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites. Parasite Immunol (2007) 1.14
Recombinant pseudorabies virus carrying a plasmodium gene: herpesvirus as a new live viral vector for inducing T- and B-cell immunity. Vaccine (1992) 1.14
Dose- and time-dependent relations between infective Anopheles inoculation and outcomes of Plasmodium falciparum parasitemia among children in western Kenya. Am J Epidemiol (1997) 1.14
Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun (1994) 1.14
Protection of mice against Plasmodium yoelii sporozoite challenge with P. yoelii merozoite surface protein 1 DNA vaccines. Infect Immun (1998) 1.12
Rehydration and maintenance therapy of cholera patients in Jakarta: citrate-based versus bicarbonate-based oral rehydration salt solution. J Infect Dis (1985) 1.11
Predicting outcome in malaria: correlation between rate of exposure to infected mosquitoes and level of Plasmodium falciparum parasitemia. Am J Trop Med Hyg (1994) 1.10
Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther (1999) 1.09
Simultaneous induction of multiple antigen-specific cytotoxic T lymphocytes in nonhuman primates by immunization with a mixture of four Plasmodium falciparum DNA plasmids. Infect Immun (1998) 1.09
HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J Immunol (1995) 1.08
Development of two monoclonal antibodies against Plasmodium falciparum sporozoite surface protein 2 and mapping of B-cell epitopes. Infect Immun (1997) 1.08
Expression of the chemokine MIG is a sensitive and predictive marker for antigen-specific, genetically restricted IFN-gamma production and IFN-gamma-secreting cells. J Immunol Methods (2001) 1.08
RII and RIII type resistance of Plasmodium falciparum to combination of mefloquine and sulfadoxine/pyrimethamine in Indonesia. Lancet (1985) 1.07
The Widal slide agglutination test, a valuable rapid diagnostic test in typhoid fever patients at the Infectious Diseases Hospital of Jakarta. Am J Epidemiol (1986) 1.06
Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine (1997) 1.05
Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther (1999) 1.04